Trial Profile
Phase 1 study of Gimeracil/oteracil/tegafur plus Paclitaxel in patient with advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Aug 2018
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 27 Aug 2018 New trial record
- 18 Aug 2018 Results published in the Investigational New Drugs